Figure 3From: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesEfficacy and safety outcomes in fragile patients and subgroups. a. Primary efficacy. b. Major bleeding. CI, Confidence interval; HR, Hazard ratio; VKA, Vitamin K antagonist.Back to article page